Lycera Corporation

Warner-lambert Company

Merck Sharp + Dohme Corp.

University of Michigan

Pharmacia & Upjohn Company

Other

Pfizer Corporation

Zoetis LLC

Pah P&u LLC

Peter Laurence Toogood

Thomas Daniel Aicher

Chad A Van Huis

Alexander Ross Hurd

Clarke Bentley Taylor

Dennis Joseph McNamara

William L Thomas

Gary D Glick

Arthur Glenn Romero

Ellen Myra Dobrusin

Richard John Booth

Mark Robert Barvian

Debra Ann Sherry

Xiao Hu

Kenneth Jay Barr

Michael R Barbachyn

Joseph Thomas Repine

John R Palmer

Vladimir Simov

John Quin, Iii

Lisa Marie Thomasco

Karin Ann Stein

Hairong Zhou

Scott Norman Vanderwel

J Craig Ruble

Paul Joseph Dobrowolski

James Bernard Kramer

Timothy Allan Johnson

Catherine M White

Blair T Lapointe

Howard Daniel Hollis Showalter

Fernando Padilla

Donald James Skalitzky

James Thomas Anderson

David Thomas Erdman

Anthony Clyde Blackburn

Edward Neil Marsh

Chad Van Huis

Gordon L Bundy

William Alexander Denny

Donna Lee Romero

Ronald G Micetich

Rajeshwar Singh

Gordon William Rewcastle

James S Kaltenbronn

Mel C Schroeder

Zhan Wang

Michael P Curtis

Chad A VanHuis

James Marino Hamby

Joseph Scott Warmus

Vladimir Genukh Beylin

Vara Prasad Venkata Nagendra Josyula

Carl J Kaub

Roy Thomas Winters

Matthew N Mattson

Manjinder Singh Lall

Chad Alan Van Huis

Gina Ney

Susanne A Trumpp-Kallmeyer

Inderjit S Sidhu

Laura Lee Celeste

Xikui Liu

Shoujun Chen

Erik Krogh-Jespersen

James Craig Ruble

Vladimar G Beylin

Gordan L Bundy

Gary E Martin

Dennis Joseph Mc Namara

Yadagiri Bathini

Carl Kaub

John Iii Quin

Michael Robert Barbachyn

Dennis Joseph Mcnamara

John Raymond Palmer

William David Thomas

The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.

Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease

The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR&#x3b3;) and provides adoptive cellular therapies using an agonist of ROR&#x3b3;, populations of lymphocyte cells that have been exposed to an agonist of ROR&#x3b3;, populations of dendritic cells that have been exposed to an agonist of ROR&#x3b3;, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR&#x3b3; to a patient.

Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods

The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR&#x3b3; activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.

Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting RORactivity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.

Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ROR&#x3b3; and the treatment of disease

The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.

Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease

The invention provides indazole guanidine compounds that inhibit FF-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

[object Object]

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR&#x3b3; activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.

Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease

Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ROR&#x3b3; activity and the treatment of disease

The invention provides saturated acyl guanidine compounds that inhibit FF-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR&#x3b3; activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR&#x3b3; activity and the treatment of disease

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR&#x3b3; activity, increasing the amount of IL-17 in a subject, and treating cancer, bacterial infections, and fungal infections using such tetrahydro[1,8]naphthyridine and related compounds.

The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting RORy activity, reducing the amount of iL-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more bicyclic sulfone compounds described herein. In certain other embodiments, the disorder is rheumatoid arthritis.

Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease

The invention provides heterocyclic guanidine compounds that inhibit FF-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides cycloalkyl guanidine compounds that inhibit FF-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.

Described herein are antibacterial compounds of formula I, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.

Tricyclic tetrahydroquinoline antibacterial agents

Growing community of inventors

Ann Arbor, MI, United States of America

Peter Laurence Toogood